Physician profile
Omar Colon
NPI 1093061293
$181,474.24
in general payments reported to CMS, 2019-2025
16 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $26K · 2021: $28K · 2022: $19K · 2023: $30K · 2024: $14K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Consulting Fee: $15K · Travel and Lodging: $4,666 · Food and Beverage: $4,090 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,320.00 |
| Consulting Fee | $15,275.00 |
| Travel and Lodging | $4,666.13 |
| Food and Beverage | $4,090.18 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $136,397.82 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| E.R. Squibb & Sons, L.L.C. | $16,510.31 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $9,911.41 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $9,778.65 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $7,130.46 | 2024-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $354.54 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $309.17 | 2019-2024 | Invega |
| Neurocrine Biosciences, INC. | $280.55 | 2020-2025 | |
| Abbvie INC. | $211.42 | 2022-2025 | Vraylar |
| Allergan, INC. | $175.17 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $144.20 | 2019-2025 | Fanapt |
| Axsome Therapeutics, INC. | $124.26 | 2024-2025 | Auvelity |
| Indivior INC. | $77.80 | 2021-2024 | Perseris |
| Lundbeck LLC | $38.80 | 2021-2025 | Rexulti |
| Luye Pharma (USA) LTD. | $18.47 | 2025 | Erzofri Extended-Release |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Colon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.